Senti Biosciences Inc

Senti Biosciences, Inc. operates as a biotechnology company. It develops gene circuit technology platforms which enable the development of next-generation cell and gene therapies. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.

Chardan NexTech Acquisition 2 Corp

NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used to support the unique needs of its clients.

Chardan Announces Launch of ChEF (Chardan Equity Facility)

- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 -

Senti Bio Reports Second Quarter Financial Results and Business Updates

The stock price of Senti Biosciences (SNTI) surged by 68.28% in the previous trading session. These are some details you should know.

Senti Biosciences (SNTI) Surged 68.28%: Details You Should Know

On most days, Senti Biosciences (NASDAQ: SNTI ) flies under the radar on Wall Street. Today, however, is different as SNTI stock is flying high.

SNTI Stock Alert: What to Know About Red-Hot Senti Biosciences Today

News for Senti Biosciences Inc Stock (SNTI)